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Abstract
Epiligrin, the major component of human keratinocyte extra-
cellular matrix, serves as the preferred integrin ligand for a3ft
in plasma membranes and focal adhesions, and colocalizes with
a684 in hemidesmosomes. In human skin, epiligrin is found in
the lamina lucida subregion of epidermal basement membrane,
where it is thought to be associated with anchoring filaments.
We have identified three patients with an acquired mucosal
predominant subepidermal blistering disease who have IgG
anti-basement membrane autoantibodies that bind the lamina
lucida/lamina densa interface of epidermal basement mem-
brane, stain cultured human keratinocyte extracellular matrix,
and immunoprecipitate disulfide linked polypeptides of 170,
145, 125, and 95 kD in human keratinocyte culture media in a
pattern identical to that of PlEl, a murine monoclonal antiepi-
ligrin antibody. Comparative immunoprecipitation studies of
patient sera, PlEl, and GB3 monoclonal antibody show that
epiligrin is identical to the antigen (i.e., BM600 or GB3 anti-
gen) previously reported to be absent from the skin of patients
with lethal junctional epidermolysis bullosa, an inherited sub-
epidermal blistering disease. Moreover, skin from a fetus with
this disease shows no evidence of reactivity to patient antiepili-
grin autoantibodies or PlEl. These studies show that antiepili-
grin autoantibodies are a specific marker for a novel autoim-
mune blistering disease and that the epidermal basement mem-
brane antigen absent in patients with lethal junctional
epidermolysis bullosa is epiligrin. (J. Clin. Invest. 1992.
90:1628-1633.) Key words: epiligrin * integrin * autoimmunity -
bullous skin diseases * epidermolysis bullosa
Introduction
The stratified squamous epithelium ofhuman epidermis is de-
rived from a proliferating basal keratinocyte cell layer that is
attached to the underlying epidermal basement membrane
(BM).' Adhesion of basal keratinocytes to epidermal BM is
1. Abbreviations used in this paper: BM, basement membrane; ECM,
extracellular matrix; LJEB, lethal junctional epidermolysis bullosa.
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critical for maintenance ofepithelial cell polarization, differen-
tiation, morphogenesis, and wound healing. Basal keratinocyte
adhesion to epidermal BM is mediated by integrin receptors
a3f31 in plasma membranes and focal adhesions, as well as a634
receptors in hemidesmosomes ( 1, 2). While these integrin re-
ceptors have traditionally been thought to bind laminins in
epidermal BM, the latter are poor ligands for adhesion of cul-
tured human keratinocytes in vitro. Recently, Carter et al. have
characterized a human keratinocyte extracellular matrix
(ECM) glycoprotein complex termed epiligrin that is the major
component of keratinocyte ECM and that serves as the pre-
ferred ligand for a3#1 in plasma membranes and focal adhe-
sions, and colocalizes with a634 in hemidesmosomes (2). In
human skin, epiligrin is found in the lamina lucida subregion
of epidermal BM adjacent to a3#1 and a34 in basal keratino-
cytes. As the major keratinocyte integrin ligand, epiligrin is
thought to play a key role in the attachment of the epidermis
to BM.
We have identified three patients with an acquired autoim-
mune blistering disease characterized by separation of the epi-
dermis from BM who have IgG anti-BM autoantibodies that
bind human skin, cultured human keratinocyte ECM, and epi-
ligrin in human keratinocyte culture media in a pattern identi-
cal to that of PlE1, a murine monoclonal antiepiligrin anti-
body. Furthermore, comparative immunoprecipitation studies
show that keratinocyte epiligrin is identical to BM600, an epi-
dermal BM antigen known to be absent from the skin ofinfants
with a lethal inherited blistering disease (lethal junctional epi-
dermolysis bullosa [LJEB]), in which the epidermis does not
adhere to BM (3, 4). These studies demonstrate that epiligrin
plays a key role in an acquired autoimmune and a lethal in-
herited blistering skin disease that are both characterized by
defective attachment of epidermis to BM.
Methods
Patients. Three patients (ages 29, 54, and 72 yr) with a mucosal pre-
dominant, subepidermal blistering disease with clinical features resem-
bling cicatricial pemphigoid (5, 6) are included in this study. All pa-
tients demonstrated involvement oforomucosal, nasopharyngeal, gen-
ital, and/or ocular mucous membranes, as well as occasional skin
lesions. Direct immunofluorescence microscopy ofnormal perilesional
skin or mucous membrane samples from these patients shows continu-
ous deposits of IgG and C3 in epidermal BM. Samples of normal fetal
skin and skin from a fetus with LJEB were provided by associates (see
Acknowledgments) and used in comparative immunostaining experi-
ments, as described below.
Reagents. FITC-conjugated goat anti-human IgG, IgA, IgM, IgE,
or fibrinogen (Tago, Inc., Burlingame, CA), peroxidase-conjugated
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goat anti-human IgG (Tago, Inc.), peroxidase- and FHTC-conjugated
goat F(ab')2 anti-mouse IgG (Tago, Inc.), murine monoclonal anti-
human IgG, (Southern Biotechnology Associates, Birmingham, AL),
GB3 murine monoclonal antibody (Accurate Chemical & Science
Corp., Westbury, NY), PlEl murine monoclonal antiepiligrin anti-
body (2), murine monoclonal antitenascin antibody (2), and protein
A-bearing, formalin-fixed staphylococci (Pansorbin; Calbiochem
Behring Corporation, San Diego, CA) were used, as described below.
Cell cultures. Human neonatal foreskin keratinocytes (Clonetics
Corp., San Diego, CA) and the A-431 human epidermoid carcinoma
cell line (American Type Culture Collection, Rockville, MD) were
grown in appropriate media at 370C in humidified 5% C02, as previ-
ously described (7).
Immunofluorescence studies. 3-mm punch biopsy samples of nor-
mal human skin were incubated in 1 M NaCl containing 1 mM EDTA,
1 mM PMSF, and 25 mM Tris-HC1 (pH 7.4) for 72 h at 4VC to produce
a substrate containing a cleavage plane between bullous pemphigoid
antigen (epidermal side) and laminin (dermal side) (8). Such 1 M
NaCl split skin serves as a sensitive substrate for detection ofantibodies
directed against subregions ofepidermal BM. Cryostat sections (6 Mm)
of 1 M NaCl split skin were incubated with serial dilutions of (a) pa-
tient serum; (b) normal human serum (negative control); (c) a refer-
ence serum sample from a patient with bullous pemphigoid (positive
control); (d) P1 El murine monoclonal antiepiligrin antibody; or (e)
murine monoclonal anti-human IgG, antibody (negative control).
Skin sections were next washed three times with PBS, stained with
FITC-conjugated goat anti-human (or where appropriate, anti-
mouse) IgG, washed three times again with PBS, and then examined by
immunofluorescence microscopy (9). Human keratinocytes and
A-43 1 cells were grown on glass slides (Lab-Tek Division, Miles Labo-
ratories, Inc., Naperville, IL) for 48 h in their respective standard me-
dia, fixed with 2% formaldehyde in PBS, and then incubated with
serum from a representative patient, normal human serum (negative
control), P1El, or murine monoclonal anti-human IgG, antibody
(negative control) for 30 min at room temperature. Cells were washed
three times with PBS then stained, washed again, and examined in the
same manner as indirect immunofluorescence microscopy studies of 1
M NaCl split skin (described above).
Immunoperoxidase studies. Cryostat sections (6 ,m) ofskin from a
human fetus with LJEB and skin from a normal human fetus were
reacted with serum from a representative patient, normal human
serum (negative control), P1 E murine monoclonal antiepiligrin anti-
body, or monoclonal antitenascin antibody (positive control), washed,
and then developed with the appropriate peroxidase-conjugated sec-
ond-step antibodies, as previously described (2).
Immunoelectron microscopy. Direct and indirect IgG immunoelec-
tron microscopy was performed as previously described (1O, 11). In
brief, a multistep immunoenzyme technique was used to characterize
in situ immunoreactants in patient skin samples, as well as IgG antiepi-
dermal BM reactivity of patients' sera, normal human serum (negative
control), PIE1, and murine monoclonal anti-human IgG, antibody
(negative control).
Biosynthetic radiolabeling of human keratinocyte culture media.
Subconfluent monolayers of human keratinocytes (to avoid con-
fluence-associated differentiation changes that occur in epithelial cell
cultures) in methionine-free media (KGM; Clonetics Corp.) were meta-
bolically labeled with [35S]methionine (50 MCi/ml; specific activity
-1100 Ci/mmol, New England Nuclear, Boston, MA) for 24 h (7,
12). Recovered culture media was made 1 mM in EDTA and PMSF,
centrifuged at 750 g for 1O min, recovered, dialyzed extensively against
0.01 M Tris-HCl, 0.15 M NaCl, pH 7.4 (Tris-buffered saline [TBS]) at
4°C, and then stored at -70°C.
Immunoprecipitation. The protein content of radiolabeled human
keratinocyte culture media aliquots was estimated by trichloroacetic
acid precipitation and used to determine equal sample inputs for im-
munoprecipitation experiments. Immunoprecipitation experiments
were performed as previously described (7, 12, 13). In brief, aliquots of
radiolabeled media were preabsorbed with normal human serum (or
normal mouse and rabbit serum in two-step immunoprecipitation stud-
ies using murine monoclonal antibodies and rabbit anti-mouse IgG),
twice mixed with freshly washed Pansorbin, then incubated overnight
at 4VC with 10 Al of serum (patient or control subjects) or murine
monoclonal antibodies. Freshly washed Pansorbin (200 Ml of a 10%
wt/vol suspension) was added to each sample for 1 h at 4VC. Pansorbin
aliquots were then washed three times with TBS containing 0.3% Tri-
ton X-100, 0.3% sodium deoxycholate, 0.3 mM NaCl, 0.1% BSA, three
times with the same buffer without BSA, and once with half ionic
strength buffer without BSA. Pansorbin, immunoglobulin, and anti-
gens were dissociated in 100 Ml of 2% SDS±0. 1 M DTT at 100IC for 2
min. Immunoprecipitation samples were recovered and studied by
SDS-PAGE and fluorography. The molecular weights of bands in
fluorographs was calculated relative to the migration of '4C-labeled
protein standards.
Affinity purification studies. To show that IgG anti-BM autoanti-
bodies in patient serum were specifically reactive with polypeptides in
human keratinocyte culture media, aliquots of patient (two subjects)
or control sera were affinity purified on lamina densa/dermal compo-
nents of 1 M NaCl split human skin ( 14). In brief, strips of lamina
densa/dermis were separately incubated with patient or control sera
( 1:5 in PBS) for 90 min at room temperature and then washed exten-
sively with PBS. Anti-BM antibodies were eluted with 20 mM sodium
citrate, pH 3.2, neutralized immediately with 2 M Tris, pH 9.0, dia-
lyzed extensively against TBS for 16 h at 4°C, and concentrated by
ultrafiltration (Centricon 30; Amicon Corp., Danvers, MA). Affinity-
purified anti-BM antibodies were analyzed in indirect immunofluores-
cence microscopy studies of 1 M NaCl split skin, as well as immunopre-
cipitation studies of radiolabeled human keratinocyte culture media.
Results and Discussion
All of our patients with blistering, erosive, and scarring lesions
of mucous membranes have circulating IgG anti-BM autoanti-
bodies that exclusively bind the dermal (rather than the epider-
mal) side of 1 M NaCl split skin (titers: 1:160, 1:5, and 1:40)
(Fig. 1 A). By immunoelectron microscopy, these patients
show in situ deposits of immunoreactants and circulating IgG
autoantibodies that bind the lamina lucida/lamina densa in-
terface of epidermal BM (Fig. 1 C). Moreover, autoantibodies
in these patients' sera immunoprecipitate a distinct set ofpoly-
peptides from culture media of biosynthetically radiolabeled
human keratinocytes. Analysis of reduced immunoprecipita-
tion samples shows that patient sera identify polypeptides of
170, 145, 125, and 95 kD (Fig. 2 A, lanes 1-3). Under nonre-
ducing conditions, these polypeptides remain disulfide linked,
migrating as a single, large protein species (2 600 kD; data not
shown). To determine whether antiepidermal BM autoanti-
bodies in patient sera (rather than some other circulating Ig
species) are responsible for immunoprecipitating these poly-
peptides, serum samples from two patients were affinity puri-
fied on lamina densa/dermal components ofepidermal BM in
1 M NaCl split skin, and then characterized in immunofluores-
cence and immunoprecipitation studies. Affinity-purified anti-
BM autoantibodies from these patients exclusively bind the
dermal side of 1 M NaCl split skin and immunoprecipitate the
same distinct set of polypeptides in keratinocyte culture media
described above (Fig. 2 B, lanes 2 and 3).
The keratinocyte polypeptides identified by these patients'
circulating autoantibodies have size characteristics, disulfide
linkages, and a distribution within cutaneous BMs such as
those oftwo previously described epidermal BM lamina lucida
constituents: epiligrin, the major keratinocyte integrin ligand
(2); and BM600, a large keratinocyte-derived glycoprotein an-
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Figure 1. IgG autoantibodies in patient serum and PlE I monoclonal antiepiligrin antibody bind only the dermal side of 1 M NaCl split skin in
indirect immunofluorescence microscopy studies (A and B, respectively), and specifically localize to the lamina lucida/lamina densa interface
of this test substrate by indirect immunoelectron microscopy (C and D, respectively). Normal human serum and control monoclonal antibody
show no evidence of reactivity to 1 M NaCl split skin in these studies (data not shown). Patient serum (E) and PlEl (F) (but not controls) show
the same pattern of reactivity to the ECM and periphery ofcultured A-43 1 cells by indirect immunofluorescence microscopy. Cultured human
keratinocytes bind IgG autoantibodies in patient serum and PlE I in the same manner as A-43 1 cells (data not shown).
tigen identified by murine monoclonal antibody GB3 (5). In-
terestingly, although the biological role of BM600 has never
been defined, previous studies have shown that this antigen is
absent in fetal skin samples from patients with LJEB (6), an
inherited blistering disease characterized by a defect within the
lamina lucida that results in separation ofepidermis from BM.
Because epiligrin and BM600 are thought to promote adher-
ence of keratinocytes to ECM in vitro and BM in vivo, it is
logical to consider their altered expression in diseases charac-
terized by separation of epidermis from BM. To assess the
identity or relatedness ofepiligrin, BM600, and antigens recog-
nized by our patients' circulating autoantibodies, comparative
immunoprecipitation experiments were performed (Fig. 2 C).
These studies show that patient sera (Fig. 2 C, lane 2), PlEl
(Fig. 2 C, lane 3), and GB3 (Fig. 2 C, lane 4) all recognize the
same set of polypeptides in keratinocyte culture media. More-
over, preabsorption of keratinocyte culture media with patient
serum (but not control normal human serum) removes all poly-
peptides reactive with patient autoantibodies, PlEl, or GB3
(Fig. 3, lanes 1-3; control studies, Fig. 3, lanes 4-6). These
immunoprecipitation studies show that epiligrin is physically
associated with the antigenic target of patient autoantibodies.
Whether the autoimmune epitopes reside on epiligrin itself is
yet to be determined. Patient sera and PlEl also demonstrate
(a) continuous staining of epidermal BM in normal human
skin by indirect immunofluorescence microscopy (Fig. 1, A
and B); (b) staining of the lamina lucida/lamina densa inter-
face ofepidermal BM by indirect immunoelectron microscopy
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(Fig. 1, Cand D); (c) staining ofthe ECM and cell periphery of
cultured human keratinocytes and A-43 1 cells, a human epi-
dermoid carcinoma cell line (Fig. 1, E and F); and (d) com-
plete absence of reactivity to a prenatal skin sample from a
patient with LJEB (Fig. 4, A and B). That epiligrin is targeted
by autoantibodies in an acquired subepidermal blistering dis-
ease and absent from the skin ofpatients with a lethal inherited
subepidermal blistering disease unify an important number of
experimental and clinical observations and provide pathologic
correlates that substantiate the key physiologic role(s) of epili-
grin in basal keratinocyte adhesion to epidermal BM.
Our findings may also have direct relevance to kalinin, a
keratinocyte-derived glycoprotein recently described by Rous-
selle et al. ( 15 ). Like epiligrin, kalinin consists ofa set of disul-
fide linked polypeptides that are present in keratinocyte ECM
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Figure 2. Patient IgG anti-BM autoantibodies immunoprecipitate a
distinct set of specific polypeptides in human keratinocyte culture
media that comparative studies show are identical to epiligrin and
BM600. (A) Analysis of reduced immunoprecipitation samples shows
that patient sera (lanes 1-3) but not control normal human serum
(lane 4) identify a set of disulfide linked polypeptides of 170, 145,
125, and 95 kD in human keratinocyte culture media; nonreduced,
this set of polypeptides remain disulfide linked and migrate as a single
large protein species (2 600 kD; data not shown). (B) Affinity-puri-
fied anti-epidermal BM autoantibodies in patient serum (representa-
tive sample, lane 3) identify the same distinct set of polypeptides (re-
ducing conditions) seen in studies of patient serum (lane 2); studies
of control human serum (lane 1) and processed control human
serum (i.e., serum subjected to the same affinity purification proce-
dures applied to patient serum, lane 4) show no evidence of reactivity
to these polypeptides. (C) Comparative immunoprecipitation studies
demonstrate that patient serum (representative sample, lane 2), an-
tiepiligrin monoclonal antibody PlEl (lane 3), and anti-BM600
monoclonal antibody GB3 (lane 4) all recognize disulfide linked
polypeptides of 170, 145, 125, and 95 kD in radiolabeled human
keratinocyte culture media. Control normal human serum (lane 1)
and control monoclonal antibody (lane 5) show no evidence of reac-
tivity to these polypeptides.
Figure 3. Biosynthetically radiola-
beled human keratinocyte culture
media was preabsorbed with pa-
tient serum or normal human
serum (control) for 2 h at 4VC,
twice mixed with freshly washed
Pansorbin, and then studied in
immunoprecipitation experi-
II ments. Analysis of immunoprecip-
itation samples (reducing condi-
tions) shows that preabsorption of
keratinocyte media with patient
serum removes all polypeptides
reactive with patient autoantibod-
ies (lane 1), PlEl (lane 2), or
GB3 (lane 3). In contrast, im-
munoprecipitation studies of kera-
tinocyte culture media preab-
sorbed with normal human serum
show that patient autoantibodies
(lane 4), PlEl (lane 5), and GB3
(lane 6) all identify the same di-
sulfide linked polypeptides. (Note:
Longer exposure of this fluoro-
graph reveals the same predomi-
nant polypeptides identified in
immunoprecipitation studies
1 2 3 4 5 6 shown in Fig. 2.)
ally, both of these proteins are thought to reside in anchoring
filaments, elements that link basal keratinocytes to lamina
densa and dermal anchoring fibrils. The molecular weights of
these polypeptides, their disulfide association, and their ultra-
structural localization in skin suggest that kalinin and epiligrin
may be the same or related glycoproteins. Moreover, studies in
our laboratories have found that autoantibodies from our pa-
tients and monoclonal antiepiligrin antibody PlE1 bind hu-
man epidermal BM, but they do not react with vascular or
renal BMs. These findings demonstrate that epiligrin has the
same tissue distribution as previously documented for kalinin
and further support the notion that these glycoproteins are
identical or closely related. Interestingly, Rousselle et al. re-
ported that skin fragments exposed to antikalinin antibodies
extensively de-epithelize as a consequence of cleavage within
the lamina lucida ( 15 ). While the mechanism of this detach-
ment is unknown, it suggests that antibodies directed against
key adhesive proteins in skin may directly cause separation of
epidermis from BM, a finding of potential relevance to the
pathogenesis of blisters seen in our patients with antiepiligrin
autoantibodies.
Antiepiligrin autoantibodies serve as a specific marker for
patients with this blistering skin disorder. We have not identi-
fied antiepiligrin autoantibodies in immunoprecipitation stud-
ies using serum from other patients with the cicatricial pemphi-
goid phenotype (n = 5), numerous other patients with subepi-
dermal blistering skin diseases (bullous pemphigoid, n = 16;
epidermolysis bullosa acquisita, n = 1; linear IgA dermatosis, n
= 1; other subepidermal bullous disease patients, n = 10) (9,
12), one skin disease control patient, or five normal volun-
teers. These findings suggest the existence of a distinct noso-
















logic entity characterized by mucosal predominant subepider-
mal blistering lesions and antiepiligrin autoantibodies. The
lack of expression of epiligrin in patients with LJEB serves as
another important example ofhow an abnormality ofepiligrin
is associated with separation ofepidermis from BM. As the key
integrin ligand for a43fl in plasma membranes and focal adhe-
sions, epiligrin has been shown to play a key role in keratino-
cyte adhesion in vitro. Findings in this report identify two dis-
ease states that attest to the importance of epiligrin in main-
taining adhesion of epidermis to BM in human skin in vivo.
Knowledge about the gene (or genes) that encodes this mole-
cule (or molecules), as well as factors that govern its (or their)
expression are of great importance in gaining a better under-
standing of epidermal structure and morphogenesis.
Figure 4. Cryostat sections (6 um) of skin
from a human fetus with lethal junctional
epidermolysis bullosa (A-D) and skin
from a normal human fetus (E-H) were
reacted with PlEl (A and E), serum from
a representative patient (B and F), anti-
tenascin (C and G; positive control), and
normal human serum (D and H; negative
control). Tenascin is expressed in the
epidermal BM of both normal and lethal
junctional epidermolysis bullosa skin (G
and C, respectively; see arrows that indi-
cate epidermal BM). In contrast, PIEI
and patient serum stain the epidermal
BM in normal (E and F, respectively) but
not diseased (A and B, respectively) skin.
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